Cipla's Yurpeak Expands Market Reach Beyond Metropolitan Areas Amid Accelerating GLP-1 Sector Growth

Cipla's Yurpeak Surpasses Expectations with Strong Sales in January 2026

Key Highlights:

• Yurpeak, Cipla's tirzepatide brand, has achieved sales of Rs 18.8 crore in January 2026, a 25.7% increase from Rs 14 crore in December 2025.
• Mounjaro, Eli Lilly's tirzepatide brand, remains the category benchmark with Rs 112.6 crore in January sales, underscoring its early-mover advantage.
• Cipla's commercial rollout of Yurpeak has been unusually wide and rapid, with a focus on tier-2 and tier-3 markets.

Market Performance:

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

• The broader tirzepatide market has scaled Rs 746 crore on a MAT January 2026 basis.
• Nuvama estimates Rs 370 crore in FY27 revenue for Yurpeak, citing Cipla's scale, distribution reach, and the GLP-1 category's early traction.

Market Trends:

• There is a growing shift in patient behavior, particularly in tier-2 and tier-3 cities, where obesity is increasingly viewed as a chronic disease rather than a cosmetic concern.
• Aspiration and health literacy are rising sharply in smaller cities, driving demand for scientific solutions and evidence-based care.
• Cipla's focus on tier-2 and tier-3 markets, combined with its wide distribution reach, is expected to make Yurpeak more accessible to patients.

Company Outlook:

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year

• Achin Gupta, Cipla's Managing Director and Global CEO Designate, maintains that semaglutide generics will expand, not cannibalize, demand for Yurpeak, citing its dual-action GLP and GIP mechanism as a preferred option.
• Dr. Rajiv Kovil, Diabetologist and Director at Zandra Healthcare, observes a structural change in how obesity is perceived, with patients increasingly seeking scientific solutions and evidence-based care.